A new drug in treatment of acne vulgaris:trifarotene
Acne vulgaris is one of the most common skin diseases in dermatology.Retinoids are commonly used in the treatment of this disease.Trifarotene is derived from CD437,a triaryl skeleton lead compound with retinoic acid receptor subtype selectivity,after the optimization of receptor structure.It is called the fourth generation retinoic acid anti-acne drug because of its high selectivity for retinoic acid y receptor(RAR-γ).In October 2019,trifarotene was approved by the U.S.Food and Drug Administration for the treatment of acne vulgaris in patients aged 9 and above.Clinical trials have shown that trifarotene is safe,effective and well tolerated in the treatment of acne vulgaris,which has a good clinical application prospect.
万方数据
维普
